Clinical Trial

Study of ALTO-101 in Patients With Schizophrenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 26, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-07-09; most recent amendment 2025-12-23.
Trial Details
NCT Number NCT06502964
Lead Sponsor Alto Neuroscience
Conditions Schizophrenia, Cognitive Impairment
Enrollment 82 participants
Start Date 2024-06-11
Primary Completion 2026-02 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-26